// App-Quantinova.ai

1081 : Anti-Leukemia Activity of the Selective BCL-2 Inhibitor ABT-199 in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia Is Characterized By MCL-1/BCL-2 Expression Serving As Biomarker for Treatment Response

Researchers

Presenter

  • Felix Seyfried

Principal Investigators

  • Salih Demir

  • Rebecca Horl

  • Stefan Kohrer

  • Annika Scheffold

  • Stephan Stilgenbauer

  • Klaus-Michael Debatin

  • Luder Hinrich Meyer

Medical Centers

  • Department III of Internal Medicine, Ulm University Medical Center, Ulm, Germany

  • Department of Pediatrics and Adolescent Medicine, University of Freiburg, Freiburg, Germany,

  • Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Venetoclax

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved